Clearside Biomedical Statistics
Share Statistics
Clearside Biomedical has 75.84M shares outstanding. The number of shares has increased by 1.5% in one year.
| Shares Outstanding | 75.84M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.47% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 64.24M |
| Failed to Deliver (FTD) Shares | 11 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 1.76M, so 2.32% of the outstanding shares have been sold short.
| Short Interest | 1.76M |
| Short % of Shares Out | 2.32% |
| Short % of Float | 2.74% |
| Short Ratio (days to cover) | 1.21 |
Valuation Ratios
The PE ratio is -2.23 and the forward PE ratio is -2.22.
| PE Ratio | -2.23 |
| Forward PE | -2.22 |
| PS Ratio | 8.79 |
| Forward PS | 5.2 |
| PB Ratio | -4.54 |
| P/FCF Ratio | -3.63 |
| PEG Ratio | n/a |
Enterprise Valuation
Clearside Biomedical Inc. has an Enterprise Value (EV) of 86.40M.
| EV / Earnings | -2.66 |
| EV / Sales | 10.5 |
| EV / EBITDA | -3.75 |
| EV / EBIT | -3.48 |
| EV / FCF | -4.34 |
Financial Position
The company has a current ratio of 4.42, with a Debt / Equity ratio of -2.64.
| Current Ratio | 4.42 |
| Quick Ratio | 4.42 |
| Debt / Equity | -2.64 |
| Total Debt / Capitalization | 161.02 |
| Cash Flow / Debt | -0.43 |
| Interest Coverage | -2.65 |
Financial Efficiency
Return on equity (ROE) is 2.04% and return on capital (ROIC) is -91.71%.
| Return on Equity (ROE) | 2.04% |
| Return on Assets (ROA) | -0.95% |
| Return on Capital (ROIC) | -91.71% |
| Revenue Per Employee | 274.20K |
| Profits Per Employee | -1.08M |
| Employee Count | 30 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -36.81% in the last 52 weeks. The beta is 2.33, so Clearside Biomedical 's price volatility has been higher than the market average.
| Beta | 2.33 |
| 52-Week Price Change | -36.81% |
| 50-Day Moving Average | 1.01 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 40.17 |
| Average Volume (20 Days) | 347.95K |
Income Statement
In the last 12 months, Clearside Biomedical had revenue of 8.23M and earned -32.48M in profits. Earnings per share was -0.53.
| Revenue | 8.23M |
| Gross Profit | 7.87M |
| Operating Income | -24.84M |
| Net Income | -32.48M |
| EBITDA | -23.06M |
| EBIT | -24.84M |
| Earnings Per Share (EPS) | -0.53 |
Balance Sheet
The company has 28.92M in cash and 43.00M in debt, giving a net cash position of -14.08M.
| Cash & Cash Equivalents | 28.92M |
| Total Debt | 43.00M |
| Net Cash | -14.08M |
| Retained Earnings | -320.92M |
| Total Assets | 29.16M |
| Working Capital | 19.52M |
Cash Flow
In the last 12 months, operating cash flow was -18.14M and capital expenditures -1.78M, giving a free cash flow of -19.91M.
| Operating Cash Flow | -18.14M |
| Capital Expenditures | -1.78M |
| Free Cash Flow | -19.91M |
| FCF Per Share | -0.32 |
Margins
Gross margin is 95.68%, with operating and profit margins of -302.02% and -394.91%.
| Gross Margin | 95.68% |
| Operating Margin | -302.02% |
| Pretax Margin | -394.91% |
| Profit Margin | -394.91% |
| EBITDA Margin | -280.31% |
| EBIT Margin | -302.02% |
| FCF Margin | -242.06% |
Dividends & Yields
CLSD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -58.24% |
| FCF Yield | -29.01% |
Analyst Forecast
The average price target for CLSD is $5.5, which is 504.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.5 |
| Price Target Difference | 504.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -17.47 |
| Piotroski F-Score | 3 |